Type 2 & other diabetes

Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes

Diabetes Obes MetabPublished Prospective before-after interventional study with control group

Authors' conclusion

Pioglitazone reduced EAT and PAT areas and improved left ventricular (LV) diastolic function in T2DM. EAT and PAT are inversely correlated (PAT less strongly) with LV diastolic function and both EAT and PAT are inversely correlated with measures of insulin sensitivity.

Study context

Population
Patients with T2D without clinically manifest CVD and subjects with normal glucose tolerance
Participants
12 vs 12
Exposure
Pioglitazone for 24 weeks in T2D; T2D vs normal glucose tolerance (NGT) at baseline
  • T2DMn = 12
  • NGTn = 12reference
Outcome
Effect of pioglitazone on epicardial (EAT) and paracardial adipose tissue (PAT), diastolic function and insulin sensitivity
Follow-up
24 weeks
Methodological detailscardiac MRI, euglycaemic insulin clamp
  • Cardiac MRI
  • Euglycaemic insulin clamp

Main finding

As reported in the abstract

EAT area decrease after pioglitazone (P = 0.03)

9%

Paracardial adipose tissue (PAT) area decrease after pioglitazone (P = 0.09)

9%

Observational data: associations, not effects.

Further findings

Metabolic effects of pioglitazone · 24 weeks

HbA1c reduction (P < 0.05)
0.9%
HDL-C increase (P < 0.05)
7%
Triacylglycerol reduction (P < 0.01)
42%
Whole-body insulin-stimulated glucose uptake increase (P < 0.01)
71%
Matsuda Index increase (P < 0.01)
100%

Left ventricular (LV) diastolic function (transmitral E/A, peak left ventricular flow rate (PLVFR)) · 24 weeks

E/A and PLVFR reduced in T2DM vs NGT (P < 0.01)
E/A and PLVFR increased after pioglitazone (P < 0.01-0.05)

Correlations at baseline

Normalized PLVFR vs EAT (P = 0.03)
r = −0.45
Normalized PLVFR vs PAT (P = 0.16)
r = −0.29
E/A vs EAT (P = 0.006)
r = −0.55
E/A vs PAT (P = 0.05)
r = −0.40
EAT and PAT vs whole-body insulin-stimulated glucose uptake (P < 0.001)
r = −0.68
EAT and PAT vs Matsuda Index (P < 0.002)
r = 0.99

Original publication

Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes. Diabetes Obes Metab. Published 4 November 2022. doi:10.1111/dom.14885

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.